002223 鱼跃医疗
2024/06 - 中期
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入4,307,612-13.50%7,971,7347,101,6796,894,3086,725,687
减:营业总成本3,182,191-9.20%5,804,4265,605,8725,382,0584,887,664
    其中:营业成本2,151,189-10.60%3,866,8703,683,6433,565,2993,182,544
               财务费用(101,308)164.44%(157,469)(96,253)(8,638)127,900
               资产减值损失(5,299)-84.51%(92,980)(104,090)(20,634)(35,977)
公允价值变动收益108-99.58%(4,106)2,1602,165(322)
投资收益21,273-42.97%143,208129,132115,831127,096
    其中:对联营企业和合营企业的投资收益3,375-60.61%11,82313,2197,80611,535
营业利润1,288,049-28.34%2,893,4941,841,8041,688,0472,009,669
利润总额1,289,304-26.72%2,848,8351,842,4181,701,8442,018,647
减:所得税费用166,410-40.11%472,362269,728217,820262,037
净利润1,122,894-24.21%2,376,4721,572,6901,484,0241,756,610
减:非控股权益2,697-121.53%(19,381)(22,348)1,602(2,452)
股东净利润1,120,197-25.02%2,395,8531,595,0371,482,4221,759,062

市场价值指针
每股收益 (元) *1.124-25.27%2.4101.6101.4901.750
每股派息 (元) *0.400--0.8000.6000.3000.300
每股净资产 (元) *12.07312.32%11.7359.8368.2527.419
审计意见 #--标准的无保留意见标准的无保留意见标准的无保留意见标准的无保留意见
回页顶
备注: *未调整数据
#只提供简体内容